Brandon G. Smaglo, M.D., FACP

Peer-Reviewed Articles

1. Smack, M, Rogers, JE, Xiao, L, Lee, SS, Pant, S, Kaseb, A, Smaglo, BG, Serpas Higbie, V, Hu, ZI, An, AW, Javle, M. Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer. Cancers 18(12), 2026. e-Pub 2026. PMID: 42352436.
2. Haldar, SD, Saj, F, Hong, SJ, Surana, R, Xiao, L, Lee, JJ, Smaglo, BG, Zhao, D, Zhu, H, Huey, RW, Willis, JA, Morelli, MP, Overman, MJ, McAllister, F, Wolff, RA, Maitra, A, Fogelman, D, Der, CJ, Pant, S. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41761573.
3. Musher BL, Vasileiou S, Smaglo BG, Robertson C, Wu M, Watanabe A, Kuvalekar M, Velazquez Y, Ketkar S, Doheyan TA, Papayanni PG, Shah A, Lapteva N, Grilley B, Buren GV, Lulla P, Heslop HE, Rooney CM, Brenner MK, M Leen AA. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nature Medicine 32(1):258-269, 2026. e-Pub 2026.
4. Lewis, KA, Lyu, H, Yammanur, M, Larsson, L, Willis, JA, Smaglo, BG, Katz, MH, Snyder, RA. Real-time implementation and validation of a natural language processing tool to improve clinical trial enrollment in pancreatic cancer. JCO Oncology Practice 21:127, 2025. e-Pub 2025.
5. Garrett A, Darzi N, Deshmukh A, Rosenfeld N, Goldman O, Adler L, Bab-Dinitz E, Singer O, Najafabadi AH, Wong CW, Bose S, Randon PM, Bustamante F, Larios R, Brandis A, Mehlman T, Smaglo B, Chang P, Oliva J, Haymaker C, Nagawekar L, Wu SR, Huang Y, Shen A, Vora A, Padilla JF, Pfeffer A, Sutherland G, Starr M, Zimmers T, Zhu Y, Morizio J, Erez A, Shen X. Vagal Blockade of the Brain-Liver Axis Deters Cancer-Associated Cachexia. Cell 188(21):1-20, 2025. e-Pub 2025. PMID: 40780194.
6. LeBleu VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, Yang S, Maldonado AS, Sugimoto H, Salvatierra ME, Solis Soto LM, Finch R, Gagea M, Fluty AC, Ludtke SJ, Lee J, Jain AK, Varadhachary G, Shroff RT, Maitra A, Shpall E, Kalluri R, Pant S. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nature Communications 16(1):8696, 2025. e-Pub 2025. PMID: 41027940.
7. Yousef A, Hurd MW, Pillai A, Chowdhury S, Snyder R, Knafl M, Lewis RL, Roy PM, Fanaeian M, Albarouki S, Castelnovo LF, Peterson J, Smaglo BG, Wolff RA, Pant S, Willis J, Huey R, Overman M, Tzeng C, Kim MP, Ikoma N, Maxwell JE, G Katz MH, Wang H, Maitra A, Koay E, Ludmir EB, Chen A, Lopez C, Ying H, Shen JP, Zhao D. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. J Hematol Oncol 18(1):44, 2025. e-Pub 2025.
8. LeBleu VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, Yang S, Maldonado AS, Sugimoto H, Salvatierra ME, Solis Soto LM, Finch R, Gagea M, Fluty AC, Ludtke SJ, Lee JJ, Jain AK, Varadhachary G, Shroff RT, Maitra A, Shpall E, Kalluri R, Pant S. KRAS (G12D) -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients. medRxiv, 2025. e-Pub 2025. PMID: 40093249.
9. Yousef, M, Hurd, MW, Yousef, A, Ludmir, EB, Balachandran Pillai, A, Peterson, J, Koay, EJ, Albarouki, S, Tzeng, CW, Snyder, RA, Katz, MH, Wang, H, Overman, MJ, Maitra, A, Pant, S, Smaglo, BG, Wolff, RA, Yao, JC, Shen, JY, Zhao, D. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist 30(1), 2025. e-Pub 2025. PMID: 39014543.
10. Ludmir, EB, Sherry, AD, Fellman, B, Liu, S, Bathala, TK, Haymaker, CL, Medina-Rosales, M, Reuben, A, Holliday, EB, Smith, GL, Noticewala, SS, Nicholas, S, Price, TR, Martin, RM, Perles, LA, Lee, SS, Lee, MS, Smaglo, BG, Huey, RW, Willis, JA, Zhao, D, Cohen, L, Taniguchi, C, Koay, EJ, Katz, MH, Wolff, RA, Das, P, Pant, S, Koong, A, Tang, C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND). Journal of Clinical Oncology 42(32):3795-3805, 2024. e-Pub 2024. PMID: 39102622.
11. Balachandran Pillai, A, Yousef, M, Yousef, A, Alfaro-Munoz, KD, Smaglo, BG, Willis, JA, Wolff, RA, Pant, S, Hurd, MW, Maitra, A, Wang, H, Katz, MH, Prakash, L, Tzeng, CD, Snyder, RA, Castelnovo, LF, Chen, A, Kravets, A, Kudriavtseva, K, Tarasov, A, Kryukov, K, Ying, H, Shen, JY, Zhao, D. Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma. Cancers 16(19), 2024. e-Pub 2024. PMID: 39410042.
12. Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K, Jawaid S, Jing J, Brisco A, Leen AM, Wu M, Sandin LC, Wenthe J, Eriksson E, Ullenhag GJ, Grilley B, Leja-Jarblad J, Hilsenbeck SG, Brenner MK, I Loskog AS. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. The lancet oncology 25(4):488-500, 2024. e-Pub 2024. PMID: 38547893.
13. Smaglo BG, Cass SH, Tzeng CD, Prakash LR, Maxwell J, Snyder RA, Kim MP, Huey RW, Smaglo BG, Pant S, Koay EJ, Wolff RA, Lee JE, G Katz MH, Ikoma N. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Ann Surg, 2024. PMID: 38506042.
14. Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, G Katz MH, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precision Oncology 8(7):27, 2024. PMID: 38310130.
15. Yousef, M, Hurd, MW, Yousef, A, Snyder, RA, Knafl, M, Fanaeian, M, Chacko, R, Peterson, J, Smaglo, BG, Wolff, RA, Pant, S, Lee, MS, Overman, MJ, Tzeng, CD, Katz, MH, Wang, H, Maitra, A, Ludmir, EB, Shen, JY, Zhao, D. Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma. Journal of Clinical Oncology 42(3_suppl):636, 2024. e-Pub 2024.
16. Ludmir, EB, Sherry, AD, Fellman, B, Liu, S, Bathala, TK, Haymaker, CL, Medina-Rosales, M, Holliday, EB, Smith, GL, Lee, MS, Zhao, D, Smaglo, BG, Taniguchi, C, Koay, EJ, Katz, MH, Wolff, RA, Das, P, Pant, S, Koong, A, Tang, C. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND). Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
17. Surana, R, Gonzalez, GN, Rogers, JE, Hong, DS, Yap, TA, Rodon Ahnert, J, Naing, A, Wolff, RA, Smaglo, BG, Meric-Bernstam, F, Subbiah, V, Pant, S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. Journal of Gastrointestinal Cancer 54(4):1308-1315, 2023. e-Pub 2023. PMID: 37119430.
18. Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Res Sq, 2023. e-Pub 2023. PMID: 37609177.
19. Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. Journal of the National Cancer Institute 115(8):994-997, 2023. e-Pub 2023. PMID: 37202363.
20. Ludford, K, Ho, WJ, Thomas, J, Raghav, KS, Blum Murphy, M, Fleming, N, Lee, MS, Smaglo, BG, You, YN, Tillman, MM, Kamiya Matsuoka, C, Thirumurthi, S, Messick, C, Johnson, B, Vilar Sanchez, E, Dasari, NV, Shin, S, Hernandez, A, Yuan, X, Yang, H, Foo, WC, Qiao, W, Maru, DM, Kopetz, S, Overman, MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
21. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Blum-Murphy M, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 41(12):2181-2190, 2023. e-Pub 2023.
22. Newhook, TE, Vreeland, TJ, Griffin, JF, Tidwell, R, Prakash, L, Koay, EJ, Ludmir, EB, Smaglo, BG, Pant, S, Overman, MJ, Wolff, RA, Ikoma, N, Maxwell, JE, Kim, M, Lee, JE, Katz, MH, Tzeng, CD. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Annals of surgery 277(3):484-490, 2023. e-Pub 2023. PMID: 36649067.
23. Newhook TE, Vreeland TJ, Griffin JF, Tidwell RSS, Prakash LR, Koay EJ, Ludmir EB, Smaglo BG, Pant S, Overman M, Wolff RA, Ikoma N, Maxwell J, Kim MP, Lee JE, Katz MGH, Tzeng CWD. Prognosis associated with CA 19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma. Ann Surg 277(3):484-490, 2023. e-Pub 2023.
24. Mahadik JD, Machado Heredia ML, Smaglo BG, Fisher WE, Dhingra S. Perineural Invasion by an Intraductal Papillary Mucinous Neoplasm of Pancreas: A Case Report of an Unusual and Unreported High-Risk Feature of Malignant Progression. Annals of clinical and laboratory science 52(5):838-842, 2022. e-Pub 2022. PMID: 36261175.
25. Hester CA, Perri G, Prakash LR, Maxwell JE, Ikoma N, Kim MP, Tzeng CD, Smaglo B, Wolff R, Javle M, Overman MJ, Lee JE, Katz MHG. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. JNCCN Journal of the National Comprehensive Cancer Network 20(8):887-897, 2022. e-Pub 2022. PMID: 35948035.
26. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal for immunotherapy of cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
27. Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clinical Cancer Research 27(12):3414-3421, 2021. e-Pub 2021. PMID: 33858857.
28. Huey, RW, Smaglo, BG, Estrella, JS, Matamoros Jr, A, Overman, MJ, Varadhachary, GR, Raghav, KS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease. Oncologist 26(4):e650-e657, 2021. e-Pub 2021. PMID: 33524217.
29. Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, S Raghav KP. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist 26(4):e650-e657, 2021. e-Pub 2021.
30. Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clin Cancer Res 26(19):5092-5101, 2020. e-Pub 2020. PMID: 32669374.
31. Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, He AR, Subramaniam DS, Deeken J, Marshall J, Pishvaian MJ. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemother Pharmacol 84(5):1145-1151, 2019. e-Pub 2019. PMID: 31538230.
32. Sada YH, Smaglo BG, Tran Cao HS, Mok H, Musher BL, Massarweh NN. National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer. J Surg Res 237:41-49, 2019. e-Pub 2019. PMID: 30694790.
33. Groth SS, Burt BM, Farjah F, Smaglo BG, Sada YH, Sugarbaker DJ, Massarweh NN. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma. J Thorac Cardiovasc Surg 157(4):1682-1693.e1, 2019. e-Pub 2019. PMID: 30711279.
34. Sada YH, Smaglo BG, Tan JC, Tran Cao HS, Musher BL, Massarweh NN. Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma. J Natl Compr Canc Netw 17(2):161-168, 2019. e-Pub 2019. PMID: 30787129.
35. Sada YH, Tran Cao HS, Chang GJ, Artinyan A, Musher BL, Smaglo BG, Massarweh NN. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer. J Surg Res 226:15-23, 2018. e-Pub 2018. PMID: 29661280.
36. Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 81(3):587-596, 2018. e-Pub 2018. PMID: 29392450.
37. Wald O, Smaglo B, Mok H, Groth SS. Future directions in esophageal cancer therapy. Ann Cardiothorac Surg 6(2):159-166, 2017. e-Pub 2017. PMID: 28447005.
38. Colton B, Hartley M, Manning MA, Carroll JE, Xiu J, Smaglo BG, Mikhail S, Salem ME. Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report. Cureus 8(1):e457, 2016. e-Pub 2016. PMID: 26918225.
39. Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D, Boland PM. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 6(41):43594-604, 2015. e-Pub 2015. PMID: 26498363.
40. Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 76(5):1073-9, 2015. e-Pub 2015. PMID: 26449224.

Invited Articles

1. Smaglo BG. Role for neoadjuvant systemic therapy for potentially resectable pancreatic cancer. Cancers 15(8):2377, 2023. e-Pub 2023.
2. Smaglo BG, Pishvaian MJ. Profile and potential of ixabepilone in the treatment of pancreatic cancer. Drug Des Devel Ther 8:923-30, 2014. e-Pub 2014. PMID: 25075175.
3. Smaglo BG, Marshall JL. Microsatellite instability in colorectal cancer 11(10):659-61, 2013. e-Pub 2013. PMID: 24518376.
4. Smaglo BG, Hwang J. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. J Gastrointest Oncol 4(3):299-307, 2013. e-Pub 2013. PMID: 23997941.
5. Smaglo BG, Pishvaian MJ. Postresection chemotherapy for pancreatic cancer. Cancer J 18(6):614-23, 2012. e-Pub 2012. PMID: 23187850.

Review Articles

1. Smaglo, BG. Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer. Cancers 15(8), 2023. e-Pub 2023. PMID: 37190305.
2. Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach. Front Surg 4:42, 2017. e-Pub 2017. PMID: 28824918.
3. Tesfaye A, Marshall JL, Smaglo BG. Approach to the medical management of surgically resectable gastric cancer. Clin Adv Hematol Oncol 14(2):129-35, 2016. e-Pub 2016. PMID: 27057811.
4. Al-Hajeili M, Marshall JL, Smaglo BG. Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer. Oncology (Williston Park) 30(1):10-6, 2016. e-Pub 2016. PMID: 26791840.
5. AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol 55 Suppl 3:S4-20, 2015. e-Pub 2015. PMID: 25707963.
6. Smaglo BG, Aldeghaither D, Weiner LM. The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol 11(11):637-48, 2014. e-Pub 2014. PMID: 25265912.
7. Smaglo BG, Marshall JL. Discordance of KRAS mutational status in a single colonic resection specimen in a patient with colorectal cancer: a case report and review of the literature. Clin Colorectal Cancer 12(3):214-7, 2013. e-Pub 2013. PMID: 23755925.

Other Articles

1. Kalantri, S, Smaglo, BG CDK4/6 inhibition in pancreatic cancer. Annals of Pancreatic Cancer 9, 2026.

Editorials

1. Kalantri S, Smaglo BG. CDK4/6 inhibition in pancreatic cancer: lessons learned as the therapeutic landscape evolves. Ann Pancreat Cancer 9(13):1-4, 2026.
2. Smaglo B. Refining the “right patient, right drug” pairing in cancer care: RAS profiling in metastatic colorectal cancer. ASCO Post 6:79, 2015.

Abstracts

1. Smaglo BG, Molina M, Arrechedera CA, Pandurengan RK, Jiang M, Ibarguen HP, Oliva-Rico DA, Mendoza-Perez JR, Sun R, Pant S, Zhao D, Le P, Willis J, Parseghian C, Bhutani M, Chishty S, Huey RW, Morelli MP, Wolff RA, Zhu H, Haldar SD, Chandrasekharan C, Braganca Xavier C, Balmaceda NB, Haymaker C, Solis-Soto LM. Changes in tumor myeloid cell composition in patients with advanced pancreatic adenocarcinoma treated with lenvatinib plus pembrolizumab in second-line or later therapy, 2026. e-Pub 2026.
2. H Lopes CD, Kasi A, Abushahin LI, Cardin DB, Lenz H, Dayyani F, Messersmith WA, Ezenwajiaku N, Oberstein PE, Paluri RK, Patel RA, Pfaff KL, Kim E, Kalyan A, Smaglo BG, Amin MA, Al Hallak MN, Gbolahan OB, Chen HX, Spreafico A. Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208). J Clin Oncol 44(suppl 16):abstr 4205, 2026. e-Pub 2026.
3. Lewis KA, Yousef MM, Prakash L, Ikoma N, Gamboa AC, Lee JE, Kim MP, Maxwell J, Tzeng CD, Smaglo BG, Zhao D, Willis J, Katz MH, Snyder RA. Distribution of driver and allele-specific KRAS mutations across racial and ethnic groups in pancreatic adenocarcinoma. J Clin Oncol 44(suppl 2):ABSTR 773, 2026. e-Pub 2026.
4. Lewis KA, Yousef MM, Prakash L, Ikoma N, Gamboa AC, Lee JE, Kim MP, Maxwell J, Tzeng CD, Smaglo BG, Zhao D, Willis J, Katz MH, Snyder RA. Racial and ethnic differences in pancreatic cancer survival and treatment at a high-volume center. J Clin Oncol 44(suppl 2):ABSTR 662, 2026. e-Pub 2026.
5. Yousef MM, Albarouki S, Elhariri A, Vetere G, Fanaeian MM, Hurd MW, Roy P, Alfaro K, Yousef AM, Smaglo BG, Wolff RA, Katz MH, Snyder RA, Pant S, Willis J, Huey RW, Overman MJ, Ludmir EB, Y Shen JP, Zhao D. Clinical outcomes and molecular characteristics of patients with metastatic pancreatic ductal adenocarcinoma according to involved metastatic sites. J Clin Oncol 43(16_suppl):ABSTR 4179, 2025. e-Pub 2025.
6. Haldar S, Saj F, Hong SJ, Surana R, Lee J, Smaglo BG, Zhao D, Zhu H, Huey RW, Willis J, Morelli MP, Overman MJ, McAllister F, Wolff RA, Maitra A, Fogelman DR, Der CJ, Pant S. A phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. J Clin Oncol 43(16_suppl):ABSTR 4152, 2025. e-Pub 2025.
7. Pant S, Smaglo B, Huey R, Haldar S, Morelli MP, Willis J, Xiao L, Yuan Y, Attanasio S, Shah R, Citron F, Zhao D, Kopetz S, Maitra A, Welsch D, Sheth R, Bhosale P, Wolff R, Viale A. A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer. J Clin Oncol 43(suppl 4):ABSTR 743, 2025. e-Pub 2025.
8. Smaglo BG, Sun R, Pant S, Lee MS, Zhao D, Le P, Javle M, Willis J, Parseghian C, Bhutani M, Saman C, Diao S, Leung M, Huey R, Morelli PM, Overman M, Wolff R. A pilot study to assess the safety, tolerability, and tumor responses with lenvatinib plus pembrolizumab in patients with advanced pancreatic ductal adenocarcinoma in second-line or later of treatment. Cancer Res 84(17), 2024. e-Pub 2024.
9. Yousef MM, Hurd MW, Yousef AM, Snyder RA, Knafl M, Fanaeian MM, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Overman MJ, Tzeng CD, G Katz MH, Wang H, Maitra A, Ludmir EB, YC Shen JP, MG Yousef DZ, Hurd MW, Yousef AM, Snyder RA, Knafl M, Fanaeian MM, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Overman MJ, Tzeng CD, G Katz MH, Wang H, Maitra A, Ludmir EB, YC Shen JP, MG Yousef DZ, Hurd MW, Yousef AM, Snyder RA, Knafl M, Fanaeian MM, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Overman MJ, Tzeng CD, G Katz MH, Wang H, Maitra A, Ludmir EB, YC Shen JP. Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 42(suppl 3):ABSTR 636, 2024. e-Pub 2024.
10. Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker CL, Medina-Rosales MN, Holliday EB, Smith GL, Lee MS, Zhao D, Smaglo BG, Taniguchi CM, Koay EJ, G Katz MH, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial. J Clin Oncol 42(suppl 3):ABSTR 603, 2024. e-Pub 2024.
11. Smaglo BG, LeBleu VS, Lee JJ, Maitra A, Kalluri R, Rezvani K, Solis-Soto LM, Hurd M, Kaur I, Mendt-Vilchez MC, Kirtley ML, Shaftoe SL, Morelli MP, Overman MJ, Zhou D, Wolff RA, Willis JA, Huey RW, Lee MS, Bhosale PR, Dworsky SW, Xu L, Pant S, Shpall EJ. iExplore: A phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation, 2023. e-Pub 2023.
12. Spiliopoulou P, Kasi A, Abushahin LI, Cardin DB, Lenz HJ, Dayyani F, Messersmith WA, Ezenwajiaku N, Oberstein PE, Paluri RK, Patel RA, Kim E, Kalyan A, Smaglo BG, Amin MA, Al Hallak MN, Gbolahan OB, Siu LL, Moscow J, Spreafico A. Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208. J Clin Oncol 40(suppl 16):ABSTR 4136, 2022. e-Pub 2022.
13. Musher BL, Smaglo BG, Abidi W, Othman M, Patel K, Jawaid S, Jing J, Brisco A, Wenthe J, Ullenhag GJ, Sandin L, Grilley B, Leja-Jarblad J, Hilsenbeck SG, Brenner MK, Rowinsky EK, Loskog ASI, Eriksson E. A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer. J Clin Oncol 40(suppl 16):ABSTR 4138, 2022. e-Pub 2022.
14. Shah AT, Huey R, Dasari P, Willett A, Smaglo BG, Matamoros A, Overman MJ, Estrella J, Raghav KPS. Cancer of unknown primary with gastrointestinal profiles: A favorable CUP subset. J Clin Oncol 40(suppl 16):ABSTR e16225, 2022. e-Pub 2022.
15. Surana R, LeBleu VS, Lee JJ, Smaglo BG, Zhao D, Lee MS, Wolff RA, Overman MJ, MEndt MC, McAndrews KM, Yang S, Rezvani K, Kalluri R, Maitra A, Shpall EJ, Pant S. Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS^G12D siRNA in patients with metastatic pancreatic cancer harboring a KRAS^G12D mutation. J Clin Oncol 40(suppl 4):TPS633, 2022. e-Pub 2022.
16. Surana R, Rogers JE, Nogueras-Gonzalez GM, Hong DS, Yap TA, Ahnert JR, Naing A, Wolff RA, Smaglo BG, Meric-Bernstam F, Subbiah V, Pant S. Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials. J Clin Oncol 40(suppl 4):577, 2022. e-Pub 2022.
17. Surana R, Lee JJ, Smaglo BG, Zhao D, Lee MS, Wolff RA, Overman MJ, Willis J, Der CJ, Pant S. Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial). J Clin Oncol 40(suppl 4):TPS634, 2022. e-Pub 2022.
18. Ludford K, Raghav KPS, Blum Murphy MA, Flemin ND, Nelson DA, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar Sanchez E, Dasari A, Thomas JV, Foo WC, Qiao W, Kopetz S, Overman MJ. Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. J Clin Oncol 39(suppl 15):ABSTR 2520, 2021. e-Pub 2021.
19. Smaglo, Musher B, Vasileiou BL, Kuvalekar S, Watanabe M, Robertson A, Wang CS, Francois T, Ramos M, Hill CA, Buren LV, Fisher G, Armaghany WE, Sada T, Valdes YV, Grilley JF, Gee BJ, Heslop AP, Lulla HE, Leen PD, Ann M. A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS). J Clin Oncol 38(suppl):ABSTR 4622, 2020. e-Pub 2020.
20. Musher BL, Smaglo BG, Abidi W, Othman M, Patel K, Jing J, Stanietzky N, Lu J, Brisco A, Wenthe J, Brenner B, Eriksson E, Leen AM, Hilsenbeck SG, Ullenhag GI, Rowinsky EK, Grilley B, Loskog ASI. A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nabpaclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: an interim report. J Clin Oncol 38(suppl 4):ABSTR 716, 2020. e-Pub 2020.
21. Smaglo BG, Musher BL, Lulla PD, Van Buren G, Fisher WE, Vasileiou S, Watanabe A, Kuvalekar M, Wang T, Robertson CS, Brisco A, Grilley BJ, Gee A, Ramos CA, Carrum G, Heslop H, Vera JF, Leen AM. Targeting pancreatic cancer using nonengineered, multiantigen specific T cells (TACTOPS). AACR Special Conference On Immune Cell Therapies for Cancer, 2019. e-Pub 2019.
22. Pishvaian MJ, Wang H, Parenti S, He AR, Hwang JJ, Ley L, Difebo H, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. Final report of a phase I/II study of veliparib in combination with 5FU and oxaliplatin (FOLFOX) in patients with metastatic pancreatic cancer. J Clin Oncol 37(suppl):ABSTR 4015, 2019. e-Pub 2019.
23. Groth SS, Burt BM, Farjah F, Smaglo BG, Sada YH, Sugarbaker DJ, Massarwah N. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma. J Thorac Cardiovasc Surg 157(4):e1, 2018. e-Pub 2018.
24. He AR, Morse M, Iyer RV, Sohal D, Wang H, Dorsch-Vogel K, Pishvaian MJ, Salem ME, Smaglo BG, Marshall JL. A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma. J Clin Oncol 35(suppl 4s):ABSTR TPS507, 2017. e-Pub 2017.
25. Philip P, Smaglo BG, El-Rayes B, Leuisse, C, Makris L. Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients compared to IS patients from the RECOURSE study. J Clin Oncol 35(suppl 4s):e15039, 2017. e-Pub 2017.
26. Sada YH, Smaglo BG, Cao HT, Akce M, Mok H, Musher B, Massarweh NM. Trends in multimodality therapy for gastric cancer post-MAGIC. J Clin Oncol 35(suppl 4s):ABSTR 148, 2017. e-Pub 2017.
27. Smaglo BG, Sada YH, Cao HT, Akce M, Mok H, Musher B, Massarweh NM. Pathologic Nodal Response in Gastric Cancer-Do All Patients Need Adjuvant Therapy?. J Clin Oncol 35(suppl 4s):ABSTR 107, 2017. e-Pub 2017.
28. Groth SS, Burt BM, Farjah F, Smaglo BG, Wald O, Sugarbaker DJ, Massarweh NM. Taking the Volume Pledge for complex cancer resections: impact on patient access and perioperative outcomes. Ann Surg, 2016. e-Pub 2016.
29. Pishvaian MJ, Wang H, Smaglo BG, Gao J, Macke L, Redmond E, Permaul ECA, Sen S, McCarthy DL, Kallakury B, Liu SV, He AR, Hwang JJ, Swain SM, Marshall JM, Pohlmann PR. A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies. J Clin Oncol 34(suppl):ABSTR 2589, 2016. e-Pub 2016.
30. Koroulakis A, Prins P, Gabrielson A, Silveri C, Hwang A, Abdulkadir S, McCullough B, Marshall J, Pishvaian MJ, He AR, Smaglo BG, Collin SP, Unger KR. A matched pair analysis of five-fraction stereotactic body radiation therapy versus protracted conventional radiation therapy in patients received chemotherapy for locally advanced pancreatic cancer. J Clin Oncol 34(suppl 4):ABSTR 444, 2016. e-Pub 2016.
31. Prins P, Bhardwaj P, Fishbein T, Johnson LB, Smith C, Satoskar R, Kim AY, Jha R, Wang H, Sullivan D, Taher S, Zhang T, Zhu J, Pishvaian MJ, Smaglo BG, Salem ME, Hartley ML, Marshall JL, He AW. The impact of multiple types of treatments on OS and the decline of liver function in patients with advanced stage of HCC. J Clin Oncol 34(suppl 4):ABSTR 461, 2016. e-Pub 2016.
32. Salem ME, Wang H, Fakih M, Mikhail S, Smaglo BG, Pishvaian MJ, He AR, Weiner LM, Bekaii-Saab TS, Marshall JL. An open-label, multi-center, phase 2 study of switch maintenance with TAS-102 plus bevacizumab following oxaliplatin or irinotecan-based fluoropyrimidine-containing induction chemotherapy in patients with metastatic colorectal cancer: ALEXANDRIA study. J Clin Oncol 34(suppl):ABSTR TPS3624, 2016. e-Pub 2016.
33. Salem ME, Xiu J, Khan SA, Wang H, Smaglo BG, El-Ceiry WS, Hwang JJ, Pishvaian MJ, Lou E, Shields AF, Philip PA, Gatalica Z, Reddy SK, Marshall JL. Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome. J Clin Oncol 34(suppl):ABSTR 4035, 2016. e-Pub 2016.
34. Salem ME, Petricoin E, Wellstein A, Pierobon M, Wang H, Mikhail S, Hartley ML, Smaglo BG, Lou E, Alistar AT, Vogel, K, Pishvaian M, He AR, Kim AY, Shivapurkar N, Reddy SK, Marshall JL. Regorafenib in metastatic colorectal cancer: an exploratory biomarker trial. J Clin Oncol 34(suppl 4):ABSTR TPS 773, 2016. e-Pub 2016.
35. Elledge CR, Lischalk JW, Gurka MK, Pishvaian MJ, Smaglo BG, He AR, Marhsall JL, Collins SP, Unger KR. Five-fraction stereotactic body radiotherapy (SBRT) in concert with chemotherapy for treatment of inoperable pancreatic adenocarcinoma. J Clin Oncol 34(suppl):ABSTR e15670, 2016. e-Pub 2016.
36. Pishvaian MJ, Wang H, He AR, Ley L, Vogel K, Hartley ML, Carnery E, Weiner LM, Smaglo BG, Brody JR, Marshall JM. A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer. J Clin Oncol 33(suppl 3):ABSTR 329, 2015. e-Pub 2015.
37. Deeken JF, Wang H, Smaglo BG, Hwang JJ, He AR, Weiner LM, Marshall J, Giaccone G, Liu SV, Luecht J, Urso C, Spiegel JY, Cheema A, Pishvaian MJ. A phase I study of intravenous artesunate in patients with solid tumors. J Clin Oncol 33(suppl):ABSTR 2535, 2015. e-Pub 2015.
38. He AW, Tesfaye A, Smith D, Marshall J, Pishvaian MJ, Smaglo BG, Weiner LM, Dorsch-Vogel K, Wang H. Phase II study of temozolamide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. J Clin Oncol 32(suppl 3):ABSTR 240, 2014. e-Pub 2014.
39. Smaglo BG, Wang H, Steadman K, Murray J, Pishvaian M, He AR, Hwang JJ, Subramaniam DS, Deeken JF, Weiner LM. A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab. J Clin Oncol 31(suppl):ABSTR TPS2624, 2013. e-Pub 2013.

Book Chapters

1. Smaglo B. Imaging diagnostics from the perspective of a medical oncologist. In: Imaging Diagnostics in Pancreatic Cancer. First Edition. Springer, 2021.
2. Smaglo BG, Aldeghaither D, Weiner LM. Antibody therapy. In: Encyclopedia of Immunobiology. First Edition. Elsevier, 2016.

Letters to the Editor

1. Yousef, M, Yousef, A, Hurd, MW, Balachandran Pillai, A, Chowdhury, S, Snyder, RA, Knafl, M, Lewis, RL, Roy, PM, Fanaeian, M, Albarouki, S, Castelnovo, LF, Peterson, J, Smaglo, BG, Wolff, RA, Pant, S, Willis, JA, Huey, RW, Overman, MJ, Tzeng, CW, Kim, M, Ikoma, N, Maxwell, JE, Katz, MH, Wang, H, Maitra, A, Koay, EJ, Ludmir, EB, Chen, A, Lopez, C, Ying, H, Shen, JY, Zhao, D. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology 18: 44, 2025.
2. Smaglo BG. In response to: AI in medical care. The Economist, 2024.
3. Smaglo BG. In response to: End-of -life care. The Economist, 2017.